SELLAS Life Sciences (SLS) Net Cash Flow Growth (3y) (2013 - 2026)
SELLAS Life Sciences (SLS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 32.17% |
| 10 | SELLAS Life Sciences | 1.84 Bn | 1.74 Bn | - | 73.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.43% |
| Dec 31, 2025 | 104.11% |
| Sep 30, 2025 | 75.15% |
| Jun 30, 2025 | -29.66% |
| Mar 31, 2025 | 59.31% |
| Dec 31, 2024 | -13.20% |
| Sep 30, 2024 | 74.00% |
| Jun 30, 2024 | -90.56% |
| Mar 31, 2024 | 61.15% |
| Dec 31, 2023 | -27.10% |
| Sep 30, 2023 | -59.04% |
| Jun 30, 2023 | -30.65% |
| Mar 31, 2023 | 145.31% |
| Dec 31, 2022 | -31.50% |
| Sep 30, 2022 | -15.80% |
| Jun 30, 2022 | 19.20% |
| Mar 31, 2022 | -37.02% |
| Dec 31, 2021 | -2.08% |
| Sep 30, 2021 | -252.48% |
| Jun 30, 2021 | 42.62% |